欢迎来到《四川大学学报(医学版)》
徐大恒, 陈霖, 唐承薇, 等. COX-2抑制剂塞来昔布对肝癌小鼠CD4+CD25+调节T细胞的影响[J]. 四川大学学报(医学版), 2013, 44(4): 545-549.
引用本文: 徐大恒, 陈霖, 唐承薇, 等. COX-2抑制剂塞来昔布对肝癌小鼠CD4+CD25+调节T细胞的影响[J]. 四川大学学报(医学版), 2013, 44(4): 545-549.
XU Da-heng, CHEN Lin, TANG Cheng-wei, et al. Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma[J]. Journal of Sichuan University (Medical Sciences), 2013, 44(4): 545-549.
Citation: XU Da-heng, CHEN Lin, TANG Cheng-wei, et al. Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma[J]. Journal of Sichuan University (Medical Sciences), 2013, 44(4): 545-549.

COX-2抑制剂塞来昔布对肝癌小鼠CD4+CD25+调节T细胞的影响

Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma

  • 摘要: 目的 探讨环氧合酶-2(cyclooxygenase-2,COX-2)抑制剂塞来昔布对肝癌小鼠调节T细胞(regulatory T,Treg)的影响。 方法 昆明种小鼠随机分成正常组及肝癌组,每组各20只。肝癌小鼠和正常小鼠于背部皮下注射肝癌H22荷瘤小鼠腹水稀释液或生理盐水0.2 mL一次。于次日开始,每组各取10只采用塞来昔布30 mg/(kg·d)灌胃;肝癌组另外10只予以相同容积的生理盐水灌胃,作为肝癌对照组。灌胃均为1次/d,共24 d。正常组另外10只不做任何干预,作为健康对照组。给药24 d后处死全部小鼠,完整取出肿瘤后称取瘤重,HE染色检测是否成瘤;采用流式细胞学技术测定小鼠外周血中Treg细胞数量变化;免疫组织化学方法检测肝癌组织中叉头样/翼状螺旋转录因子-3(Foxp3)及COX-2的表达情况。 结果 塞来昔布干预后小鼠瘤重低于肝癌对照组(0.82±0.30)g vs.(1.41±0.63)g,P<0.05。HE染色证实所有肿瘤小鼠均已成瘤。肝癌对照组小鼠外周血中Treg占CD4+T细胞的比例高于健康对照组(4.26±0.89)% vs.(3.01±0.65)%,P<0.05;经塞来昔布作用后,其Treg占CD4+T细胞的比例下降(3.04±0.74)% vs.(4.26±0.89)%,P<0.05。正常小鼠经塞来昔布作用后,其外周血Treg与健康对照组相比无明显变化。塞来昔布干预后肝癌小鼠肿瘤浸润淋巴细胞中Foxp3蛋白阳性细胞低于肝癌对照组(8.87±3.72)% vs.(30.78±9.26)%,P<0.05,肿瘤组织中COX-2表达水平亦下调IOD值(2.90±1.030)vs.(6.63±2.279),P<0.01。 结论 肝癌小鼠外周血中Treg比例增高;COX-2抑制剂能明显降低其外周血及肿瘤浸润淋巴细胞中Treg的比例。

     

    Abstract: Objective To investigate the effect of celecoxib on regulatory T cells (Treg) in mouse hepatocellular carcinoma (HCC). Methods Total of 40 mice was divided into two subgroups, normal animal groups include control and celecoxib group, HCC groups include control and celecoxib group. 30 mg/kg of celecoxib were given daily for 24 days for celecoxib groups. All mice were sacrificed after 24 days treatment and the removed tumor weight were measured. By detecting CD4 and CD25 with flow cytometry, the level of Treg in peripheral blood was determined. The expressions of Forkhead/winged helix transcription factor-3 (Foxp3) protein in the tumor infiltrating lymphocytes (TILs) and cyclooxygenase-2(COX-2) protein in tumor tissue were measured by immunohistochemistry techniques. Results The mean weight of tumor in celecoxib group is much lower than that of control group (0.82±0.30) g vs. (1.41±0.63) g, P<0.05. The percentage of Treg in total CD4+T cells isolated from the peripheral blood of HCC animals in control group was higher than that of normal control group (4.26±0.89)% vs. (3.01±0.65)%, P<0.05. After treatment with celecoxib, the percentage of Treg was decreased (3.04±0.74)% vs. (4.26±0.89)%, P<0.05 and the percentage of Foxp3 positive cell in TILs was also decreased (8.87±3.72)% vs. (30.78±9.26)%, P<0.05. The tumor tissue COX-2 protein expression in celecoxib group was lower than in that of control group IOD (2.90±1.030) vs. (6.63±2.279), P<0.01) and the changing of COX-2 in tumor tissue was according to Treg in the peripheral blood. Conclusion Treg cells are increased in the peripheral blood of HCC mice and COX-2 inhibitor could decrease the percentage of Treg cell in the peripheral blood or TILs.

     

/

返回文章
返回